91ÌÒÉ«ÊÓƵ

91ÌÒÉ«ÊÓƵ To Release First in Patients Data At The 2017 ASH Meeting On Autologous Fecal Microbiota Transfer And Restoration Of Microbiota Diversity

The French Microbiome company completed its first clinical study proving that Autologous Fecal Microbiota Transfer induced a 90% recovery of gut microbiome diversity. These promising results could open new avenues for treating several conditions in the hematology-oncology field.

(Lyon-France) – November 30, 2017 – 91ÌÒÉ«ÊÓƵ, a French-based microbiome company developing innovative treatments for unmet medical needs in hematology-oncology, infection diseases and immune diseases such as GvHD, announces that data related to MaaT011* will be the subject of one poster presentation at the 59th American Society of Hematology (ASH) Annual Meeting and Exhibition on December 9-12 in Atlanta, USA.

*Product: Enema administration of MaaT011, Autologous Fecal Microbiota suspension, targeting diversity
restoration following iatrogenic dysbiosis.The presentation details are as follows:

• Abstract Title: Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transplantation (auto-FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive / Treatment (ODYSSEE study): First Results of a Prospective Multicenter Trial
• Date: Sunday, December 10, 2017, 6:00 PM-8:00 PM
• Location: Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)
• Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II
• Presented by: Dr Florent Malard1 & Dr Emilie Plantamura2
• Abstract: #2624
• Link: https://ash.confex.com/ash/2017/webprogram/Paper102744.html

This presentation underlines the medical rationale of the use of FMT in hematology-oncology. The design of the ongoing Phase I/II study, in Acute Myeloid Leukemia will also be explained.Auto-FMT induced a recovery of microbiota diversity as high as 90% at the genus level and a return to the baseline of the resistance gene copy-count. A safety review by an external Data Safety Monitoring Board (DSMB) recently confirmed the safety profile of the product in this very fragile patient population.Patients’ profiles are currently being reviewed to assess clinical outcomes.

Microbiome research, an Investment for the Future

Recent findings in microbiome research are promising and open new therapeutic pathways for physicians and patients in infectious diseases, cancer, immuno-deficient diseases, obesity, autism, etc. Meanwhile, scientific publications and investments in biotech companies specialized in the microbiome have multiplied.
For example, the United States has chosen to launch in 2016 “The National Microbiome Initiative” with a fund of more than $120 million for research. France also supports biotech companies like 91ÌÒÉ«ÊÓƵ in this field, through its PIA investment program. 91ÌÒÉ«ÊÓƵ is the first MicrobioTech to use GMP Compliant Fecal Microbiota Transfers (FMT) in patients.

Following its Proof of Concept using MaaT011, 91ÌÒÉ«ÊÓƵ currently develops drug products using autologous and allogeneic microbiota transfers. Driven by its exponential growth, 91ÌÒÉ«ÊÓƵ has teamed up with Biocodex to develop an oral form of its drug. A step further towards industrialization of FMT for this MicrobioTech company, which has developed the first CE marked device for stool collection and dilution.

About 91ÌÒÉ«ÊÓƵ

Founded at the end of 2014, 91ÌÒÉ«ÊÓƵ (Microbiota as a Therapy), a microbiome–based biopharmaceutical company, revolutionizing and shaping a selective approach to therapies in order to treat debilitating diseases linked to gut microbiota imbalances. Thanks to the €16 million in funding 91ÌÒÉ«ÊÓƵ is currently developing a range of FMT products for patients suffering from hematology-oncology, infection diseases and immune diseases such as GvHD to optimize the success of the harsh medical treatment associated. 91ÌÒÉ«ÊÓƵ’s revolutionary and rapid approach plays a considerable part in the evolution of tailored treatment therapies.

Thanks to a strong scientific and medical network, the company is increasing its partnerships with renowned institutions such as INRA, and Bioaster and is part of a consortium coordinated by Institut Gustave Roussy to improve the efficacy of immunotherapies. In the coming months, 91ÌÒÉ«ÊÓƵ will significantly pursue its development programs in hematological and infectious indications and is preparing its next fundraising with the objective of launching an oral formulation of the FMT drug product by 2018.

91ÌÒÉ«ÊÓƵ is backed by its investors who are experts in the Microbiome field and in technological developments:
Seventure, CM-CIC Innovations, Biocodex and INRA.

For additional information, please visit www.maatpharma.com or follow us on Twitter @MaaT_Pharma.